Lifeline Screening is an organization that stops health problems even before they strike the body. Lifeline Screening offers dozens of services. However, their most used test is their vascular test. Due to so many Americans having strokes in recent years, Lifeline Screening has put together the ultimate vascular test.
The Vascular test can take 30 to 60 minutes. The professional physicians search for any sign of vascular problems when administering the test. Lifeline Screening physicians use state-of=the-art ultrasound equipment to administer their vascular test. This equipment will quickly show if there are any signs of vascular problems within the patient’s body. The physicians who work for Lifeline Screening have been taught to thoroughly search through the human body. A traditional visit to the doctor does not compare to a visit to a Lifeline Screening center.
If the physicians believe the problem is urgent, the patient will be sent to the nearest hospital immediately. Otherwise, the patient can leave, and his/her results will arrive in the mail within one week. Lifeline Screening urges all patients to take their results to their family doctor as soon as they arrive in the mail.
Lifeline Screening accepts all insurances, and they even offer low monthly payments for people who have no insurance. Additionally, do not be alarmed in thinking a Lifeline Screening center is thousands of miles away. There is a Lifeline Screening center in all major cities and surrounding cities in America. Within the next two years, Lifeline Screening plans to have a center in every city in America.
Lifeline Screening also has doctors of all languages on staff, so every person in America has the opportunity to have an efficient vascular test performed on them. Doctors believe by the beginning of next year, Lifeline Screening will be credited with preventing at least ten thousand people from having vascular problems.
Oncotarget is a weekly, online, open-access, peer-reviewed medical journal that provides in-depth articles, papers and research information on all areas of oncology. Founded in 2010, it is published by Impact Journals. Noted cancer researchers and professors Mikhail Blagosklonny and Andrei V. Gudkov are Oncotarget’s editors-in-chief. Abstracted and indexed in Scopus, Science Citation Index Expanded, BIOSIS Previews and Medicus/MEDLINE/PubMed, Journal Citation Reports gives the journal an Impact factor of 5.168. Oncotarget has an online archive of its articles, however, each issue can also be printed on special demand.The term “oncotarget” covers all of the molecules, cellular functions and pathways common in cancer and aging, cancer cells and microbes, lymphocytes and neurons as well as neurodegeneration and atherosclerosis. Oncotarget’s online popularity is continually rising. This is due in part to its insightful, punctual, constructive, multiple peer-review process. This helps authors to increase their research’s impact.
The mission of the multidisciplinary journal is to make the results of scientific research being cone worldwide rapidly and widely available. Oncotarget also aims to eliminate the barriers between specialties and link the different areas of biomedical science. The publication also fosters applications of both basic and clinical science to help fight disease.Guided by the leadership of some of the world’s most prominent scientists, Oncotarget helps all researchers to be able to contribute to scientific progress. The ultimate goal is life without disease. The scientific community has so readily embraced the publication that Oncotarget has now launched sections on topics beyond oncology. The journal now accepts papers on Aging, Autophagy, Cardiology, Cell Biology, Cell Diseases, Chromosome, Endocrinology, Immunology, Metabolism, Neuroscience, Pathology, Pharmacology, Stem Cell and many other areas.
Oncotarget editorial board members Nobel prize winner Andrew Schally and former Cancer Research editor-in-chief Carlo M. Croce have had a combined 37 papers published in Oncotarget. Since 2013, Alexander Varshavsky, Bert Vogelstein, Stephen J. Elledge and Michael N. Hall, all members of Oncotarget/Oncoscience/Gerotarget, have won the Breakthrough Prize, the highest prize for scientific research.The authors give permission for anyone to copy, download, distribute, reprint, reuse or modify any articles that is published in Oncotarget. However, the original authors of the articles as well as its source must be properly cited. This policy is designed to aid in the dissemination of the information contained in the publication. This helps to give as many people as possible the opportunity to learn from the material.
Amicus Therapeutics, Inc. is a leading new frontier global biotechnology company based in Cranbury, New Jersey. This innovative company researches new discovery findings, the development, and adopting therapies for devastating rare and orphan diseases. Amicus Therapeutics has a vigorous line of one-of-a-kind small molecules called ‘pharmacological chaperones.’ The chaperones provide dual-treatment to bind, stabilize and increase the activity of a patient’s own deformed enzymes to potentially improve enzyme replacement therapy outcome.
Amicus Therapeutics, Inc., research and development processes began as a result of Megan Crowley, who was diagnosed with Pompe disease which she had been suffering with since the age of one. Pompe is a progressive muscle and respiratory weakening disease with a high mortality rate. Megan’s father, John Crowley is now the CEO of this biotechnology company which has a pipeline of therapies for human genetic diseases like his daughter has. Mr. Crowley is determined to find a cure for his daughter and many others who suffer from rare, unexplored diseases (https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm). His quest has made Amicus Therapeutics a leader for the drug industry and has made them champions in the development of new medical treatments and programs.
Fabry is also an early age disease that affects millions around the world, just like the Pompe disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. Both diseases require daily medical assistance to manage and control the complications of these devastating diseases affecting multiple organ systems. To find a cure for the Fabry disease, the Pompe disease, and other chronic diseases, Amicus Therapeutics is investigating enzyme replacement therapy, influencing chaperone advanced replacement therapy, taking a lead in the clinical development of topical medicine to treat genetic connective tissue disorders, including investigating many other scientific first treatments and discovery programs.
Amicus Therapeutics is leading the fight in developing a topical therapy for the treatment of lesions and blisters that appear on the skin and in some cases on the lining of other body organs. This rare, chronic disease is known as Epidermolysis Bullosa. Epidermolysis Bullosa can potentially become disfiguring, and in some cases fatal. Amicus Therapeutics has also taken the lead recently in promising finds for the underlying cause of muscle damage and weakness in Pompe patients. This pioneering company has a three-fold promise, which is to remain at the forefront of therapies for rare and orphan diseases, to build long-term value for stakeholders and to foster teamwork and respect for each individual’s contribution.
Maggie Gill the President and Chief Executive Officer of Memorial Health, situated Savannah, Georgia. Gill has been with Memorial Health since 2004; from 2004 to 2011 she was the hospital’s Chief Operating Officer before being promoted. Prior to her taking over as President and CEO, Memorial Health had experienced several years of red ink. After her promotion, the hospital began earning profits again. Maggie Gill graduated from Florida State University in 1993 with a Bachelor’s Degree in English Language and Literature/Letters. She earned her M.B.A. in Business Administration from Saint Leo University in 1998.
Gill started her professional career at Tenet Healthcare where she served as the Chief Financial Officer for 10 years. She was very effective at her job and earned the Outstanding CFO Award for 3 consecutive years in 2001, 2002, and 2003. In addition, she has served as a Board Member at four nonprofits; the Union Mission, the Georgia Chamber of Commerce, Mercer University, and the Georgia Hospital Association.
One of Maggie Gill’s proudest achievements was how her team did in 2016 when the Georgia Medical Society held its 16th Annual Health Care Heroes Awards. During the presentation, Memorial Health’s team won seven awards. Among the award was one for their Health Care Education initiative that educated young drivers about safe driving. Another winner the hospital’s Infectious Disease Response Team. Two physicians won LifeTime Achievement awards; Carl Boyd, M.D. who was a trauma surgeon, and Linda Sacks, M.D. who is a former neonatologist.
For the last few years, Gill had been working on a transaction with Novant Health where Novant would purchase Memorial Health. Unfortunately, negotiations were stymied by the Chatham County Hospital Authority. Gill has stated that the authority became overly involved in the discussions and this resulted in Memorial Health being pulled in two different directions by two different government authorities. If the agreement had come to fruition it would have resulted in a necessary cash infusion into Memorial Health, to the tune of $295 million over the next 10 years.
When she is not working, Maggie Gill loves to spend time with her husband and two young children. They love outdoor activities and try to go into the outdoors every weekend. Among their favorite things to do is to go on hikes, go fishing, and camp overnight.